Aurobindo Pharma’s wholly owned subsidiary -- CuraTeQ Biologics has received Notice of Compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva, its bevacizumab biosimilar. Health Canada issues an NOC after a successful review, granting formal marketing authorization to the biosimilar by confirming it meets regulatory standards for safety, efficacy, and quality - comparable to the reference biologic drug under the Food and Drug Regulations.
Bevacizumab, a humanized monoclonal antibody, inhibits angiogenesis - the formation of new blood vessels - by blocking vascular endothelial growth factor A (VEGF-A). This action slows tumor vascular growth and treats multiple cancers, including colorectal and lung. Available in 100 mg and 400 mg formulations, the originator product Avastin is marketed by Roche/Genentech.
In 2025, Bevqolva secured marketing authorization from the MHRA and launched commercially for patients across the UK. The product is currently under review by the CHMP with the European Medicines Agency. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.20 |
| Dr. Reddys Lab | 1322.95 |
| Cipla | 1309.90 |
| Zydus Lifesciences | 891.65 |
| Lupin | 2303.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: